IP Library Granted Patent US 9,993,475
Granted Patent B2
US 9,993,475 · App. 15/360,304 · Granted Jun 12, 2018

Method for treating a pulmonary hypertension condition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,993,475
App. No.
15/360,304
Granted
Jun 12, 2018
Kind
B2
Abstract

A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.

Claims (6)

1. A method for treating a human patient exhibiting a pulmonary arterial hypertension (PAH) of WHO Class IV at baseline, comprising orally administering to the patient a therapeutically effective amount of ambrisentan.

2. The method of claim 1 , wherein the PAH is further associated with a connective tissue disease (CTD).

3. The method of claim 1 , wherein the ambrisentan is administered in a daily dosage amount of about 1 mg to about 25 mg.

4. The method of claim 3 , wherein the ambrisentan is administered in a daily dosage amount of about 2.5 mg to about 10 mg.

5. The method of claim 4 , wherein the administration continues for 12 weeks.

6. The method of claim 1 , wherein the administration is initiated within 2 years following diagnosis of the PAH condition.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2017
From: DUFTON, CHRISTOPHER; GERBER, MICHAEL J.
To: GILEAD SCIENCES, INC.
Reel/Frame 044007/0492 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2017
From: GILEAD COLORADO, INC.
To: GILEAD SCIENCES, INC.
Reel/Frame 044011/0123 →